Q1 FY27 Results: Consolidated revenue up 30% YoY, PAT declines 8%

Revenue Growth 20pctResults View source PDF Explain this filing

POLYMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.8%Reaction day

₹1709.30

prior close

₹1704.70

announcement price

In-mkt

timing

Nifty Smallcap 250market-0.0%-0.8% vs market

Medical Equipment & Supplies peers, median of 12sector+0.0%-0.8% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Smallcap 250 and 0.8 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

-1.0

15m

-0.8

30m

-0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.8-0.0-0.8+0.0-0.8

Next day

+3.7-0.1+3.8-0.5+4.2

+9.1+0.1+9.0-3.8+12.9

+9.9-0.1+10.0-2.4+12.3

+5.6+0.0+5.6-1.9+7.5

+4.3-0.4+4.8+0.0+4.3

+4.5-0.1+4.5-2.5+7.0

15d

+1.7+0.7+0.9-1.8+3.5

-0.1+0.7-0.8-4.0+4.0

-5.6-2.4-3.2-3.7-1.9

—————

UpDownMarket · Nifty Smallcap 250Sector · Medical Equipment & Supplies peers, median of 12Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Poly Medicure Q1 FY27: Consolidated revenue grew 30% YoY to Rs 525.38 cr from Rs 403.21 cr, helped by subsidiary consolidation. Standalone revenue rose 12% to Rs 431.10 cr. Consolidated PAT fell 8% to Rs 85.27 cr from Rs 93.08 cr. Standalone PAT was flat at Rs 88.12 cr. Board granted 1,476 ESOPs, allotted 1,975 shares, re-appointed Cost Auditors, and accepted Deputy CS Ravi Prakash's resignation effective Aug 10.

Likely market impact

Strong top-line growth from subsidiaries offset by lower PAT; minor ESOP grant and key management change.